Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Zevaquenabant
Cat. No.:
OB0425LY-129
Appearance:
Solid
Purity:
≥95%
Identity:
Confirmed by NMR.
Size:
Add to basket
Product Overview
Description:
Zevaquenabant is a pyrazole derivative with potential neuroprotective or anti-inflammatory properties.
Synonyms:
Zevaquenabant; 1998760-00-1; (S)-MRI-1867
CAS No.:
1998760-00-1
Compound CID:
122525002
Formula:
C25H21ClF3N5O2S
Formula Weight:
547.98
Specification
Target:
Cannabinoid receptor; NO synthase
Pathway:
GPCR/G protein; Neuronal signaling; Immunology/Inflammation
Storage:
Storage at -20°C.
Applications:
Zevaquenabant can be used to improve chronic kidney disease (CKD) caused by obesity.
